1448664-46-7
1448664-46-7
Chemical Structure
Enfortumab
Synonym(s): AGS-22C3
- CAS No.: 1448664-46-7
- Formula:N/A
- Molecular Weight:(145.44 kDa)
IUPAC Name: N-(4-(chlorodifluoromethoxy)phenyl)-5'-fluoro-2-oxo-2H-[1,3'-bipyridine]-5-carboxamide
SMILES: [Enfortumab]
Biological Activity: Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab does not contain the K214R/D356E/L358M mutations. Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enfortumab | 99.90% | Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab does not contain the K214R/D356E/L358M mutations. Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Enfortumab (powder) | Enfortumab (powder) is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody agent conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab (powder) can be used for the study of locally advanced and metastatic urothelial carcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Challita-Eid PM, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016 May 15;76(10):3003-13. [Content Brief]
- [2]. O'Donnell PH, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. [Content Brief]
